Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

35 antineoplastic-naïve patients with advanced/metastatic renal cell carcinoma (mRCC) newly started on pazopanib, mean age 61.9 years, 57% male, treated at a single academic medical center in the United States.

Pazopanib (starting dose 800 mg daily in 91% of patients, 400 mg daily in 9%)

Development of pazopanib-induced hypertension and cardiovascular adverse events, defined using the National Cancer Institute's Common Terminology Criteria for Adverse Events v4.0safety